BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 36376922)

  • 1. Prognostic value of tumor-infiltrating immune cells and immune checkpoints in elderly head-and-neck squamous cell carcinoma patients undergoing definitive (chemo)radiotherapy.
    Rühle A; Todorovic J; Spohn SSK; Gkika E; Becker C; Knopf A; Zamboglou C; Sprave T; Werner M; Grosu AL; Kayser G; Nicolay NH
    Radiat Oncol; 2022 Nov; 17(1):181. PubMed ID: 36376922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypoxia dynamics on FMISO-PET in combination with PD-1/PD-L1 expression has an impact on the clinical outcome of patients with Head-and-neck Squamous Cell Carcinoma undergoing Chemoradiation.
    Rühle A; Grosu AL; Wiedenmann N; Mix M; Stoian R; Niedermann G; Baltas D; Werner M; Weber WA; Kayser G; Nicolay NH
    Theranostics; 2020; 10(20):9395-9406. PubMed ID: 32802199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Digital pathology-aided assessment of tumor-infiltrating T lymphocytes in advanced stage, HPV-negative head and neck tumors.
    de Ruiter EJ; de Roest RH; Brakenhoff RH; Leemans CR; de Bree R; Terhaard CHJ; Willems SM
    Cancer Immunol Immunother; 2020 Apr; 69(4):581-591. PubMed ID: 31980916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-L1 expression correlates with tumor-infiltrating lymphocytes and better prognosis in patients with HPV-negative head and neck squamous cell carcinomas.
    Sanchez-Canteli M; Granda-Díaz R; Del Rio-Ibisate N; Allonca E; López-Alvarez F; Agorreta J; Garmendia I; Montuenga LM; García-Pedrero JM; Rodrigo JP
    Cancer Immunol Immunother; 2020 Oct; 69(10):2089-2100. PubMed ID: 32448984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
    Yang WF; Wong MCM; Thomson PJ; Li KY; Su YX
    Oral Oncol; 2018 Nov; 86():81-90. PubMed ID: 30409325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics and impact of programmed death-ligand 1 expression, CD8+ tumor-infiltrating lymphocytes, and p16 status in head and neck squamous cell carcinoma.
    Ngamphaiboon N; Chureemas T; Siripoon T; Arsa L; Trachu N; Jiarpinitnun C; Pattaranutaporn P; Sirachainan E; Larbcharoensub N
    Med Oncol; 2019 Jan; 36(2):21. PubMed ID: 30666437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiotherapy for geriatric head-and-neck cancer patients: what is the value of standard treatment in the elderly?
    Haehl E; Rühle A; David H; Kalckreuth T; Sprave T; Stoian R; Becker C; Knopf A; Grosu AL; Nicolay NH
    Radiat Oncol; 2020 Feb; 15(1):31. PubMed ID: 32019576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A retrospective analysis of tumor infiltrating lymphocytes in head and neck squamous cell carcinoma patients treated with nivolumab.
    Kuba K; Inoue H; Matsumura S; Enoki Y; Kogashiwa Y; Ebihara Y; Nakahira M; Yamazaki T; Yasuda M; Kaira K; Kagamu H; Sugasawa M
    Sci Rep; 2022 Dec; 12(1):22557. PubMed ID: 36581686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of immune response biomarkers (PD‑L1, p16, CD3+ and CD8+ TILs) in recurrent head and neck squamous cell carcinoma within previously irradiated areas.
    Pflumio C; Thomas J; Salleron J; Faivre JC; Borel C; Dolivet G; Sastre-Garau X; Geoffrois L
    Oncol Rep; 2021 Mar; 45(3):1273-1283. PubMed ID: 33432367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of antibiotic administration on the outcomes of head-and-neck squamous cell carcinoma patients undergoing definitive (chemo)radiation.
    Rühle A; Zou J; Glaser M; Halle L; Gkika E; Schäfer H; Knopf A; Becker C; Grosu AL; Popp I; Nicolay NH
    Eur Arch Otorhinolaryngol; 2023 May; 280(5):2605-2616. PubMed ID: 36764957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic and Predictive Relevance of Tumor-Infiltrating Lymphocytes in Squamous Cell Head-Neck Cancer Patients Treated with Radical Radiotherapy/Chemo-Radiotherapy.
    Koukourakis IM; Gkegka AG; Xanthopoulou E; Nanos C; Giatromanolaki A; Koukourakis MI
    Curr Oncol; 2022 Jun; 29(6):4274-4284. PubMed ID: 35735451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients.
    Kim HR; Ha SJ; Hong MH; Heo SJ; Koh YW; Choi EC; Kim EK; Pyo KH; Jung I; Seo D; Choi J; Cho BC; Yoon SO
    Sci Rep; 2016 Nov; 6():36956. PubMed ID: 27841362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The tumor immune microenvironment and its implications for clinical outcome in patients with oropharyngeal squamous cell carcinoma.
    Gurin D; Slavik M; Hermanova M; Selingerova I; Kazda T; Hendrych M; Shatokhina T; Vesela M
    J Oral Pathol Med; 2020 Oct; 49(9):886-896. PubMed ID: 32516834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic and clinicopathological significance of PD-L1 and tumor infiltrating lymphocytes in hypopharyngeal squamous cell carcinoma.
    Hu C; Tian S; Lin L; Zhang J; Ding H
    Oral Oncol; 2020 Mar; 102():104560. PubMed ID: 31923855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The differences of immunologic and TP53 mutant phenotypes between synchronous and metachronous head and neck cancer and esophageal cancer.
    Chen TC; Wu CT; Wang CP; Lou PJ; Ko JY; Chang YL
    Oral Oncol; 2020 Dec; 111():104945. PubMed ID: 32769036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of tumor PD-L1 expression combined with CD8
    Wang Q; Lou W; Di W; Wu X
    Int Immunopharmacol; 2017 Nov; 52():7-14. PubMed ID: 28846888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma.
    Lechner A; Schlößer H; Rothschild SI; Thelen M; Reuter S; Zentis P; Shimabukuro-Vornhagen A; Theurich S; Wennhold K; Garcia-Marquez M; Tharun L; Quaas A; Schauss A; Isensee J; Hucho T; Huebbers C; von Bergwelt-Baildon M; Beutner D
    Oncotarget; 2017 Jul; 8(27):44418-44433. PubMed ID: 28574843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumour-infiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancer.
    Balermpas P; Michel Y; Wagenblast J; Seitz O; Weiss C; Rödel F; Rödel C; Fokas E
    Br J Cancer; 2014 Jan; 110(2):501-9. PubMed ID: 24129245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor Infiltrating Lymphocytes are Prognostic Factors and Can Be Markers of Sensitivity to Chemoradiotherapy in Head and Neck Squamous Cell Carcinoma.
    Suzuki H; Kawasaki Y; Miura M; Hatakeyama H; Shina K; Suzuki S; Yamada T; Suzuki M; Ito A; Omori Y
    Asian Pac J Cancer Prev; 2022 Apr; 23(4):1271-1278. PubMed ID: 35485685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression level of PD-L1 is involved in ALDH1A1-mediated poor prognosis in patients with head and neck squamous cell carcinoma.
    Zhou AL; Wang X; Yu W; Yang L; Wei F; Sun Q; Wang Y; Kou F; Dong R; Ren X; Zhang X
    Pathol Res Pract; 2020 Sep; 216(9):153093. PubMed ID: 32825960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.